Descrizione del progetto
Una nuova tecnologia per una terapia endovenosa più sicura
La terapia endovenosa è una procedura diffusa ma non priva di rischi per gli operatori sanitari e per i pazienti. Ad esempio, lo spostamento endovenoso accidentale e l’embolia gassosa vascolare sono critici per i pazienti e annualmente costano decine di miliardi di euro al sistema sanitario. Il progetto SAFE-Infusion, finanziato dall’UE, sta sviluppando nuove tecnologie che contribuiranno a prevenire gli spostamenti accidentali e a rimuovere le bolle gassose pericolose mantenendo un sistema chiuso. Inoltre, tale progetto sta rendendo l’infusione endovenosa più intelligente grazie all’uso di sensori connessi a internet. Ciò consentirà ovunque una visibilità in tempo reale per gli operatori sanitari e renderà l’assistenza ospedaliera e quella domiciliare più sicure, poiché gli operatori potranno essere avvisati istantaneamente tramite un pannello di controllo riguardo a variazioni nel trattamento prescritto.
Obiettivo
Intravenous (IV) therapy is the most performed invasive treatment with 3.8 bn disposables tubes used annually. This procedure is not safe, neither for healthcare personnel nor patients, with serious consequences such as accidental IV dislodgement and Vascular Air Embolism (VAE) generating additional healthcare costs of €43b every year. In addition, there is a growing trend to administer IV infusion at home presenting social and economic benefits to patients with chronic diseases, cancer and, being especially important, to the current aging European population. In views of the situation, there is an urgent need for IV therapy risk reduction by preventing dislodgement, VAE and spill of hazardous fluids/vapours, while simultaneously supporting the ‘bringing care home initiative’.
In response, we have developed ReAL, a weak-link tube connection and air removal devices that will make IV therapy more accurate and safer for healthcare personnel and patients by i) preventing accidental dislodgement, and ii) removing harmful air bubbles in a closed system,. ReAL helps patients to receive a more accurate dose with faster recovery, while healthcare providers save money. Providing IV therapy at home has shown a 90% potential cost saving compared to corresponding care provided in the hospital.
In this SAFE-Infusion project we aim to disrupt the IV tube market by maturing, testing, and launching the next- generation tube connection and air removal device. Within the first five years post project, we estimate total accident-related cost-savings of €3.3bn for healthcare (i.e. €28 for each €1 spent in ReAL), 57 tonnes of plastic waste saved, €114m in accumulated revenues and €44m in accumulated operating profit for the SAFE-Infusion industry partners together.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
IA - Innovation actionCoordinatore
111 39 Stockholm
Svezia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.